Background and purpose: Neuromyelitis optica (NMO) or Devic′ s disease is a rare
inflammatory and demyelinating autoimmune disorder of the central nervous system (CNS) …

Background Spasticity is a common problem in multiple sclerosis (MS) patients causing
pain, spasms, loss of function and difficulties in nursing care. A variety of oral and parenteral …

Background: Neuromyelitis optica (NMO) is an uncommon, life-threatening inflammatory
demyelinating disorder. Recently, much has become known about its immunopathogenesis …

Neuromyelitis optica and neuromyelitis optica spectrum disorders have been recently
associated with the disease-specific autoantibody aquaporin-4, thought to be pathogenic …

Prompt treatment of neuromyelitis optica (NMO) relapses with steroids or plasma exchange
(PLEX) often prevents irreversible disability. The objective of this study is to report the use of …

Background In 2002, the UK's National Institute for Clinical Excellence (NICE) concluded
that interferon beta and glatiramer acetate would be cost effective as disease-modifying …

Objectives We have undertaken a clinic-based survey of neuromyelitis optica spectrum
disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence …

For most patients presenting with a spinal cord syndrome MR scanning has become the key
investigation in establishing the diagnosis. However, myelopathy with normal spinal imaging …

Discussion. Natalizumab is a humanized recombinant monoclonal antibody interfering with
the interaction of VLA-4 with its natural ligand, vascular cell adhesion molecule (VCAM-1) …

Objectives In 2002, the UK's National Institute for Health and Care Excellence concluded
that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer …